Potential protective effect of zoledronic acid when switching from long-term therapy of osteoporosis with denosumab
In accordance with the data of the Federal Clinical Recommendations for the Diagnosis, Treatment and Prevention of Osteoporosis, with the latter, antiresorptive drugs (denosumab, bisphosphonates) are used, which mainly suppress bone resorption, and anabolic compounds (teriparatide), which enhance bo...
| Published in: | Медицинский совет |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2021-01-01
|
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/5983 |